tbuckley/cabot-search huggingface dataset:
P0580 : Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome
Authors: V. Svicher, R. Salpini, L. Colagrossi, A. Battisti, M.C. Bellocchi, C. Alteri, D. Armenia, F. Di Santo, L. Carioti, M. Pollicita, A. Ricciardi, M. Lichtner, C. Mastroianni, M. Paoloni, M. Marignani, S. Maylin, C. Delaugerre, F. Morisco, N. Coppola, A. Marrone, D. Di Paolo, C. Sarrecchia, L. Sarmati, M. Andreoni, M. Angelico, C.F. Perno
Journal: Journal of Hepatology (2015)
MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults
Authors: Corinna La Rosa, Jeff Longmate, Joy Martinez, Qiao Zhou, Teodora I. Kaltcheva, Weimin Tsai, Jennifer Drake, Mary Carroll, Felix Wussow, Flavia Chiuppesi, Nicola Hardwick, Sanjeet Dadwal, Ibrahim Aldoss, Ryotaro Nakamura, John A. Zaia, Don J. Diamond
Journal: Blood (2016)
More cases of tuberculosis than previously thought, WHO reports
Authors: Anne Gulland
Journal: BMJ (2016)

The global incidence of tuberculosis (TB) is higher than previously thought, after it was found that earlier estimates of the disease were too low.

According to the World Health Organization’s Global Tuberculosis Report 2016 , there were 10.4 million cases of the disease worldwide in 2015.1 Last year’s report put the figure at 9.6 million cases,2 but WHO says this figure is incorrect.

Six countries accounted for nearly 60% of the total burden, with India having the highest number of cases at 2.84 million. Last year’s report estimated that 2.2 million people had TB in India, but this figure has now been revised to 2.9 …
Comment on Rubino et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care 2016;39:861–877
Authors: Jens Aberle, Burkhard Göke
Journal: Diabetes Care (2016)

We read with interest the article by Rubino et al. (1). The authors suggest treatment with metabolic surgery after conservative therapy does not reach individual diabetes targets in patients with BMI >30 kg/m2. They recommend sodium–glucose cotransporter 2 (SGLT2) inhibitors as suitable drugs, among others, for early postoperative diabetes management due to their low risk of inducing hypoglycemia.

The use of SGLT2 inhibitors has been associated with an increased risk for euglycemic diabetic ketoacidosis (DKA) in type 1 and type 2 diabetes. More than …
A girl with an abnormal gait
Authors: Yong-Hai Zhou, Ming-Hua Zheng
Journal: BMJ (2016)

A 1 year old girl presented to the paediatric orthopaedic clinic with abnormal gait. Her parents noticed that she had a “duck-like” waddle when she had first started to walk a month previously. On examination, there were asymmetrical skin creases on her buttocks, and her legs were of similar length. There were no other external congenital malformations. Anteroposterior radiography of the infant’s pelvis was carried out (fig 1⇓). What is the diagnosis?



Fig 1 

### Answer

Bilateral developmental dysplasia of the hip.

### Discussion

The image shows changes typical of developmental dysplasia of the hip (DDH). …
Author’s reply: Regarding the editorial by Penttinen and Friede
Authors: Pasi M Penttinen, Martin H Friede
Journal: Eurosurveillance (2016)

Preview this article: Author’s reply: Regarding the editorial by Penttinen and Friede, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/21/40/eurosurv-21-30367-4-1.gif
Prevention of Acute GvHD during Haplo-BMT: Evaluating the Efficacy of T-Cell Costimulation Blockade Using a Novel Rhesus Macaque Transplant Model
Authors: Weston Miller, Caleb E. Wheeler, Angela Panoskaltsis- Mortari, Allan Kirk, Christian P Larsen, Bruce R Blazar, Leslie Kean
Journal: Blood (2008)
Can [F-18]FDG PET imaging predict early response to chemotherapy in breast cancer patients?
Authors: C. S. John, R. Madabushi, C. Farah, C. Lubas, G. Williams
Journal: Journal of Clinical Oncology (2009)

e14577 Background: The purpose of this study was to perform a meta-analysis of literature data and see if [F-18]FDG and PET imaging can be used to predict the early response to chemotherapy based upon the measure of standard uptake value (SUV) or drug uptake ratio (DUR; a measure of glycolytic index) in breast cancer patients. This intervention may identify the responders for continued therapy or identify the non- responders for change of therapy. Methods: A literature search determined the number of studies that used PET-FDG imaging to monitor the response of various chemotherapies in breast cancer patients. A total of nine studies have been reviewed that used SUV/DUR as a measure of glycolytic activity of the primary tumors. The percent decrease of SUV over baseline was determined for chemotherapy cycle 1 and for subsequent cycles. A paired t-test was performed to see the statistical significance of the SUV decrease. Results: Five (n=158) studies presented the data in % mean reduction in SUV and four (n=59) studies presented SUV values for the individual patient. The average decrease in SUV in responders were 29% and 51% after first and second cycle, respectively. The non responders did not show significant change in SUV as compared to responders. Conclusion: The preliminary data mining and analysis strongly implies that PET imaging using [F-18]FDG may be used to monitor the progress of chemotherapy in breast cancer patients. This study was supported by a grant from OWH, FDA. The results do not represent official FDA position. No significant financial relationships to disclose.
Reading Bly in the Waiting Room
Authors: Brent Christianson
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of bexarotene on platelet counts in patients undergoing cancer treatment: An analysis of clinical trials in lung cancer and leukemia
Authors: D. E. Tsai, W. Wang, R. Reshef, D. Vogl, E. Stadtmauer, C. Andreadis, A. Carlson, S. Luger
Journal: Journal of Clinical Oncology (2009)

e20533 Background: Bexarotene (Bex) is an oral retinoid X receptor agonist with activity against cutaneous T cell lymphoma and currently under investigation for other malignancies. In patients receiving this agent for acute myeloid leukemia (AML), we noted increases in platelet counts. We therefore reviewed the available clinical trial data on Bex and its effects on platelet counts. Methods: We analyzed platelet count data from 3 Bex clinical trials encompassing non-small cell lung cancer (NSCLC) and AML. Results: In two phase III trials of Bex in NSCLC, patients underwent carboplatin + paclitaxel (CarP, n=587) or cisplatin + vinorelbine (CisV, n=613) and were randomized to receive concurrent Bex or placebo. More patients on Bex than on placebo had an increase in platelet count of at least 50 K/uL (55% vs. 27% for CarP, p&lt;0.0001; 81% vs. 66% for CisV, p&lt;0.0001) over pre-treatment baseline. The median increase in platelet count was higher on Bex than on placebo (69 vs 0 K/uL for CarP, p&lt;0.0001; 168 vs. 95 K/uL for CisV, p&lt;0.0001) and was maintained while on treatment. In both NSCLC trials, the median time to platelet increase &gt;50 K/uL on Bex was 22 days. Similar findings were seen in a phase I monotherapy trial in AML where 5/18 (28%) patients achieved platelet transfusion independence with peak platelet counts of 40–91 K/uL. Conclusions: Clinically significant increases in platelet counts were seen in all 3 clinical trials examined. These data suggest that Bex improves platelet counts in patients with a variety of cancer types, both as monotherapy and with concurrent chemotherapy. Its effect on megakaryopoiesis and its potential role as a supportive care measure should be further evaluated. [Table: see text]
Immunotherapy of Primary Ovarian Cancer Using Autologous Cytokine Induced Killer Cells Retargeted with Bispecific Antibodies: A Preclinical Study.
Authors: John K. Chan, Chad A. Hamilton, Michael K. Cheung, Mobin Karimi, Jeanette Baker, Jonathan M. Gall, Lawrence G. Lum, Stephan Schulz, Steve H. Thorne, Nelson N. Teng, Christopher H. Contag, Robert S. Negrin
Journal: Blood (2005)
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
Authors: Olivier Mir, Thomas Brodowicz, Antoine Italiano, Jennifer Wallet, Jean-Yves Blay, François Bertucci, Christine Chevreau, Sophie Piperno-Neumann, Emmanuelle Bompas, Sébastien Salas, Christophe Perrin, Corinne Delcambre, Bernadette Liegl-Atzwanger, Maud Toulmonde, Sarah Dumont, Isabelle Ray-Coquard, Stéphanie Clisant, Sophie Taieb, Cécile Guillemet, Maria Rios, Olivier Collard, Laurence Bozec, Didier Cupissol, Esma Saada-Bouzid, Christine Lemaignan, Wolfgang Eisterer, Nicolas Isambert, Loïc Chaigneau, Axel Le Cesne, Nicolas Penel
Journal: The Lancet Oncology (2016)
Identification of a molecular profile that may predict early relapse in patients undergoing multimodality therapy in muscle-invasive bladder cancer (MIBC).
Authors: S. A. Hussain, D. H. Palmer, D. H. Ward, J. R. Arrand, S. I. Collins, D. Barton, A. Martin, E. Porfiri, M. Wallace, N. D. James
Journal: Journal of Clinical Oncology (2010)

e15118 Background: The aim of this study was to investigate the outcome in patients (pts) with MIBC receiving neo-adjuvant chemotherapy (neo-CT) prior to organ-preservation (chemo-radiation) or cystectomy and to correlate with translational studies. Methods: Pts with stage T2-T4N0M0TCC bladder with GFR ≥40ml/min were eligible. Neo-CT comprised gemcitabine (1,000 mg/m2 d1, d8, q21) plus cisplatin (35 mg/m2 d1, d8, q21) for 4cycles. Following neo-CT pts underwent surgery or RT with or without concurrent chemotherapy (CRT) based on response to neo-CT and clinician and pt preference. Bladder biopsy samples and blood samples were stored for RNA and proteomic analysis respectively. Results: 23 pts were recruited: 21 males 2 females; median age 69 yrs (range 49-85); stage T2=11,T3A=7,T3B=5, G2=1, G3=22. 1 pt progressed before neo-CT. 75 cycles of neo-CT were administered and was well tolerated with only 1 neutropenic sepsis episode. 3/22 pts developed early PD and did not receive radical treatment. For the remaining 19 pts,choice of definitive treatment (surgery vs. RT/CRT) was based on response to neo-CT.8 pts had residual disease at post-neoCT cystoscopy;6 underwent surgery and 2 RT/CRT. 11 pts had CR to neo-CT,9 of whom were treated by RT/CRT,with the remaining 2 declining radical treatment. MFU was 42.8 months(m).Median survival was 25.3m (CI 17.4- 47.7). 4/6 and 8/11 pts who underwent cystectomy and organ preservation treatment respectively remain alive.We have used MALDI-TOF mass spectrometry to profile the proteomes of the sera available for 15 pts.The data suggest differences between the pre neo-CT serum proteomes of pts dying within 6m(n=4) and pts surviving more than 12m(n=10).Total cellular RNA extracted from 27 tumour samples from 19 pts and from 8 normal samples from 8 pts proved to be of suitable quality for Affymetrix array analysis. Conclusions: Neo-CT is well tolerated in MIBC. Translational studies incorporating proteomic and molecular profiling may identify patients with a poor outlook who may be better served by immediate radical treatment. A further study in a larger cohort of 200 pts is planned. No significant financial relationships to disclose.
Temporal Trends in Predictors of Early and Late Mortality After Emergency Coronary Artery Bypass Grafting for Cardiogenic Shock Complicating Acute Myocardial Infarction
Authors: Piroze M. Davierwala, Sergey Leontyev, Alexander Verevkin, Ardawan J. Rastan, Matthias Mohr, Farhad Bakhtiary, Martin Misfeld, Friedrich W. Mohr
Journal: Circulation (2016)

Cardiogenic shock after acute myocardial infarction is an indication for emergent coronary artery bypass grafting in patients not amenable to percutaneous coronary intervention. Our study aimed to evaluate and identify risk factors for early and long-term outcomes in such patients.A total of 508 patients who underwent coronary artery bypass grafting for cardiogenic shock complicating acute myocardial infarction between January 2000 and June 2014 were divided into 3 time cohorts: 2000 to 2004 (n=204), 2005 to 2009 (n=166), and 2010 to 2014 (n=138). Predictors of in-hospital mortality for each time cohort and long-term mortality for all patients were identified by logistic and Cox regression analyses, respectively.Mean age was 68.3±9.8 years. Of the 508 patients, 78.5% had 3-vessel and 47.1% had left main disease. Left ventricular function <30% was observed in 44.1% of patients, with 30.4%, 37.9%, 52.9%, and 3.1% requiring preoperative resuscitation, ventilation, intra-aortic balloon pump, and extracorporeal membrane oxygenation support, respectively. Overall in-hospital mortality was 33.7%; declined from 42.2% to 30.7% to 24.6%, respectively, for the 3 time cohorts (P=0.02); and was independently predicted by serum lactate >4 mmol/L (odds ratio [OR], 4.78; 95% confidence interval, 2.88-7.95; P<0.0001), ST-segment-elevation myocardial infarction (OR, 2.10; 95% confidence interval, 1.36-3.26; P=0.001), age >75 years (OR, 2.01; 95% confidence interval, 1.06-3.85; P=0.03), and left ventricular ejection fraction <30% (OR, 1.83; 95% confidence interval, 1.15-2.91; P=0.01). Cumulative survival was 42.6±2.0% and 33.4±2.0% at 5 and 10 years, respectively, and correspondingly improved to 64.3±3.0% and 49.8±3.0% in hospital survivors. Serum lactate >4 mmol/L (OR, 2.2; P<0.0001), incremental age (OR, 1.05; P<0.0001), New York Heart Association class IV (OR, 1.33; P=0.02), diabetes mellitus (OR, 1.39; P=0.005), and preoperative inotropic (OR, 2.61; P=0.001) and extracorporeal membrane oxygenation (OR, 1.68; P=0.05) support predicted late mortality.Emergency coronary artery bypass grafting in patients with acute myocardial infarction complicated by cardiogenic shock is associated with a high in-hospital mortality, which showed a significant decline with time. Hospital survivors have good long-term outcomes, which demonstrate the beneficial effect of surgical revascularization. Preoperative serum lactate >4 mmol/L is a strong predictor of both early and late mortality.
A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances
Authors: Alena A. Chekmasova, Holly M. Horton, Tracy E. Garrett, John W. Evans, Johanna Griecci, Amanda Hamel, Howard J. Latimer, Stacie L. Seidel, Byoung Y. Ryu, Michael Kuczewski, Christopher J. Horvath, Kevin M. Friedman, Richard A. Morgan
Journal: Blood (2015)
GW26-e2365 Association of C5aR1 Genetic Polymorphisms With Pathogenesis and Prognosis of Coronary Artery Disease in Xinjiang Han and Uygur Population
Authors: Yingying Zheng, Xiang Xie, Yining Yang, Zhenyan Fu, Xiaomei Li, Shuo Pan, Dilare Adi, Bangdang Chen, Fen Liu, Yitong Ma
Journal: Journal of the American College of Cardiology (2015)
Modulation of the molecular arrangement in artificial and biological membranes by phospholipid-shelled microbubbles
Authors: Dario Carugo, Miles Aron, Erdinc Sezgin, Jorge Bernardino de la Serna, Marina K. Kuimova, Christian Eggeling, Eleanor Stride
Journal: Biomaterials (2016)

The transfer of material from phospholipid-coated microbubbles to cell membranes has been hypothesized to play a role in ultrasound-mediated drug delivery. In this study, we employed quantitative fluorescence microscopy techniques to investigate this phenomenon in both artificial and biological membrane bilayers in an acoustofluidic system. The results of the present study provide strong evidence for the transfer of material from microbubble coatings into cell membranes. Our results indicate that transfer of phospholipids alters the organization of molecules in cell membranes, specifically the lipid ordering or packing, which is known to be a key determinant of membrane mechanical properties, protein dynamics, and permeability. We further show that polyethylene-glycol, used in many clinical microbubble formulations, also has a major impact on both membrane lipid ordering and the extent of lipid transfer, and that this occurs even in the absence of ultrasound exposure.
Soluble Interleukin-2 Receptors (sIL-2R) Is An Independent Prognostic Factor for Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP
Authors: Noriko Nishimura, Masahiro Yokoyama, Kengo Takeuchi, Naoko Tsuyama, Eriko Nara, Kazuhito Suzuki, Kenji Nakano, Kyoko Ueda, Yuko Mishima, Sakura Sakajiri, Shunji Takahashi, Yasuhito Terui, Kiyohiko Hatake
Journal: Blood (2011)
Phase II study of fixed dose rate gemcitabine in patients with pretreated advanced colorectal cancer
Authors: G. Chong, N. Starling, A. R. Norman, G. Brown, J. Thomas, P. J. Ross, D. C. Cunningham
Journal: Journal of Clinical Oncology (2006)

13558 Background: There is preclinical evidence that gemcitabine has activity in colon cancer. However, previous clinical studies have not clearly demonstrated activity of gemcitabine given as a 30 minute infusion. Prolonged exposure of colon cancer cell lines to gemcitabine appears to have greater antitumour effect compared to shorter exposure (Kornmann et al, Eur J Surg Oncol 2000). Methods: Patients with progressive, pretreated metastatic colorectal cancer received gemcitabine 1500 mg/m 2 at a fixed dose rate of 10 mg/m 2 /min (150 minutes) D1, 8, 15 every 28 days. The primary endpoint was disease control rate (CR/PR/SD) assessed by CT scan. Using a 2-stage statistical design, a total of 37 patients were required to demonstrate at least a 25% disease control rate with 90% power and a 1-sided alpha of 0.05. The 1 st accrual stage required at least 6/17 pts to obtain disease control, prior to proceeding to the 2 nd stage. Results: 16 patients with a median age of 63 years were treated. The median number of prior lines of chemotherapy was 3 (range: 1–5). The median number of administered gemcitabine doses was 5.5 (range: 1–14). 3 patients achieved SD after 3 cycles, but subsequently progressed. 13 patients either progressed prior to the first scheduled CT scan or had declining performance status requiring removal from the study. 1 patient experienced transient reduction in serum CEA of &gt; 50%. Median progression-free survival was 77 days (95% CI 61–93). Grade 3/4 neutropenia occurred in 4/1 pts; grade 3/4 thrombocytopenia in 6/0 pts. 2 pts had grade 3 infection. As only 3/16 pts achieved disease control, it was not possible to proceed to the 2 nd stage and the study was closed to accrual. Conclusions: Gemcitabine administered by fixed dose rate infusion has minimal activity in heavily pretreated patients with advanced colorectal cancer. Gemcitabine monotherapy is not recommended in this patient population. No significant financial relationships to disclose.
Darbepoetin alfa Administered Every 3 Weeks Is Effective in Correcting Hemoglobin and Reducing Transfusion Requirements in Anemic Patients with Hematological Malignancies Receiving Chemotherapy: A Retrospective Observational Study Reflecting Real-World Clinical Practice in Europe.
Authors: Bertrand Coiffier, David Coeffic, Frank Strohbach, Marcus Schweigert, Hirsh Koyi, Lisa Hamilton, Tamás Suto
Journal: Blood (2007)
Evaluation of Molecular Response by Real-Time RT-PCR in Acute Promyelocytic Leukemia (APL): A Direct Comparison with Regular RT-PCR.
Authors: Jiong Hu, Yuan-Fang Liu, Yong-Mei Zhu, Shu-Jiang Zhang, Bai-Wei Gu, Zhi-Xiang Shen, Jiong Hu
Journal: Blood (2005)
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Authors: S. Genadieva-Stavrik, A. Boumendil, P. Dreger, K. Peggs, J. Briones, P. Corradini, A. Bacigalupo, G. Socié, F. Bonifazi, H. Finel, A. Velardi, M. Potter, B. Bruno, L. Castagna, R. Malladi, N. Russell, A. Sureda
Journal: Annals of Oncology (2016)
GW26-e4759 The Anti-atherosclerotic Effect of Pseudolaric acid B in High-Fat Fed ApoE Knockout Mice: Alterations in Circulating and Atherosclerotic Plaque Monocytes/Macrophages and The Underlying Mechanisms
Authors: Xiao Li, Xin Zhou, Tan Li, Yu-Xiu Li, Tie-Min Jiang, Yu-Ming Li, Ji-Hong Zhao
Journal: Journal of the American College of Cardiology (2015)
A phase I study with exploratory pharmacodynamic endpoints of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients (pts) with advanced solid malignancies
Authors: H. A. Wakelee, J. R. Molina, J. M. Fehling, J. L. Lensing, B. I. Sikic
Journal: Journal of Clinical Oncology (2007)

14044 Background: XL647 is an orally bioavailable small molecule inhibitor of multiple receptor tyrosine kinases involved in tumorigenesis, angiogenesis, and metastasis, including EGFR/ErbB1, ErbB2/HER2, VEGFR2/KDR, and EphB4. In a previous Phase I study, the MTD was 350 mg when XL647 was dosed orally for 5 consecutive days every 14 days. Of 41 pts treated, one pt with NSCLC achieved a PR and 14 pts had prolonged stable disease (3.5–14+ months). The purpose of the present study is to determine the MTD of XL647 administered orally on a continuous daily schedule. Methods: Pts are enrolled in successive cohorts to receive XL647 daily for repeated 28 day cycles. PK sampling is performed to determine Cmax, and AUC at each dose level. Plasma samples are analyzed by ELISA for mechanism-of-action related molecules. Eyebrow hair bulbs are being evaluated by IHC to monitor effects of XL647 on signal transduction pathways downstream of EGFR. Tumor response is assessed every 8 weeks by RECIST. Pts remain on study until PD or unacceptable AEs. Results: Twelve pts have been enrolled. The starting dose was 75 mg (n=3) and has been escalated to150 mg (n=3), 200 mg (n=3) and 300 mg (n=3). To date, dose escalation continues as no DLTs have occurred and the MTD has not been determined. Ten pts remain on study, including 4 with stable disease for at least 3 months. In cohort 2, eyebrow samples from 3 pts were analyzed. XL647 caused a significant reduction in the phosphorylation of the EGFR downstream signaling kinases AKT (up to 73%) and ERK (up to 78%) in 2/3 and 3/3 pts, respectively. Preliminary analysis of potential plasma protein biomarkers from pts in cohorts 1 and 2 showed a trend towards upregulation of PlGF plasma levels in 4/6 pts during XL647 treatment. Conclusions: XL647 is well-tolerated when administered daily at doses tested to date. Dose escalation will continue until the MTD is defined. Analysis of eyebrow samples demonstrated its feasibility as a potential surrogate epidermal tissue for assessing inhibition of EGFR downstream targets by XL647. Updated safety, PK and pharmacodynamic results will be presented. [Table: see text]